Sustainable analytical approach devised for complex drug formulation
The innovative method uses spectroscopy and could enhance pharmaceutical quality assurance in resource-limited settings, the study suggests.
List view / Grid view
The innovative method uses spectroscopy and could enhance pharmaceutical quality assurance in resource-limited settings, the study suggests.
The system is distinguishable from other bacterial expression systems and can be applied in scenarios where minimal endotoxin contamination is an issue, according to the research.
The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
Analysis cites personalised medicine, outsourcing and digitalisation as some of the key factors set to advance the pharmaceutical analytical testing market to 2032.
The new approach involving refinement and optimisation of ionisable lipids could accelerate the development of mRNA therapies, research suggests.
The new executive recruits at Amgen and Pfizer will support advancement in therapeutic areas including oncology and rare disease.
With fluorescence imaging an essential tool in noninvasive biomedical research, the microscopy advancement holds opportunity for progress in optical imaging, according to the paper.
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
This bioproduction investment in Lyon, France supports Sanofi in its goals to lead in the immunology sector.
The new name and logo represent BeiGene’s vision to eliminate cancer through global collaborations to widen its reach for patients.
The acquisition is set to strengthen BioNTech’s capabilities in development and manufacture of next-generation bispecific antibodies.
Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
This investment supports AstraZeneca’s strategy to drive the biopharma company's development in the US.
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.